Literature DB >> 22302065

Systemic immunoglobulin G4 (IgG4) disease and idiopathic orbital inflammation; removing 'idiopathic' from the nomenclature?

D Lindfield1, K Attfield, A McElvanney.   

Abstract

The discovery of systemic disease related to raised tissue and serum immunoglobulin G4 (IgG4) is changing diagnostic and therapeutic practice in many medical specialties. Orbital inflammation remains a diverse and heterogeneous group of disorders that can pose a diagnostic and therapeutic challenge, but with improved understanding and corresponding diagnostic advances the previously expansive group of idiopathies is reducing. The recent discovery that IgG4 has a causative role in a subtype of, what is currently termed, idiopathic orbital inflammation is encouraging. The term 'idiopathic' can now be removed from the nomenclature for another subtype of orbital inflammation. IgG4 disease should be especially considered in patients with a bilateral dacryoadenitis and systemic features (eg, lung and gastrointestinal involvement). However, reports are emerging suggesting that IgG4 may be responsible for more diverse disease subtypes. The relationship between IgG4-related disease and lymphoma remains unknown but vigilance is required.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22302065      PMCID: PMC3351067          DOI: 10.1038/eye.2012.4

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  43 in total

1.  Placental transfer of IgG subclasses in a Japanese population.

Authors:  S Hashira; S Okitsu-Negishi; K Yoshino
Journal:  Pediatr Int       Date:  2000-08       Impact factor: 1.524

2.  IgG4-positive plasma cells specifically infiltrate various organs in autoimmune pancreatitis.

Authors:  Terumi Kamisawa
Journal:  Pancreas       Date:  2004-08       Impact factor: 3.327

3.  Marginal zone B-cell lymphoma of the salivary gland arising in chronic sclerosing sialadenitis (Küttner tumor).

Authors:  E R Ochoa; N L Harris; B Z Pilch
Journal:  Am J Surg Pathol       Date:  2001-12       Impact factor: 6.394

4.  The immunoarchitecture of the normal human lacrimal gland. Relevancy for understanding pathologic conditions.

Authors:  R Wieczorek; F A Jakobiec; E H Sacks; D M Knowles
Journal:  Ophthalmology       Date:  1988-01       Impact factor: 12.079

5.  Immunoglobulin G4 (IgG4)-positive or -negative ocular adnexal benign lymphoid lesions in relation to systemic involvement.

Authors:  Toshihiko Matsuo; Kouichi Ichimura; Yasuharu Sato; Yasushi Tanimoto; Katsuyuki Kiura; Sou Kanazawa; Toshiaki Okada; Tadashi Yoshino
Journal:  J Clin Exp Hematop       Date:  2010

Review 6.  Current concepts on Riedel thyroiditis.

Authors:  Giampaolo Papi; Virginia A LiVolsi
Journal:  Am J Clin Pathol       Date:  2004-06       Impact factor: 2.493

7.  Radiation treatment of orbital lymphoid hyperplasia.

Authors:  J S Kennerdell; B L Johnson; M Deutsch
Journal:  Ophthalmology       Date:  1979-05       Impact factor: 12.079

8.  Treatment of idiopathic inflammatory orbital pseudotumours by radiotherapy.

Authors:  J C Orcutt; A Garner; J M Henk; J E Wright
Journal:  Br J Ophthalmol       Date:  1983-09       Impact factor: 4.638

Review 9.  Diagnosis and management of orbital pseudotumor.

Authors:  Dina Jacobs; Steven Galetta
Journal:  Curr Opin Ophthalmol       Date:  2002-12       Impact factor: 3.761

10.  Radiotherapy for idiopathic inflammatory orbital pseudotumor. Indications and results.

Authors:  R C Sergott; J S Glaser; K Charyulu
Journal:  Arch Ophthalmol       Date:  1981-05
View more
  9 in total

1.  Rituximab in IgG4-related inflammatory disease of the orbit and ocular adnexae.

Authors:  D Lindfield
Journal:  Eye (Lond)       Date:  2012-07-20       Impact factor: 3.775

Review 2.  Ocular myositis.

Authors:  Clare L Fraser; Simon E Skalicky; Avinash Gurbaxani; Peter McCluskey
Journal:  Curr Allergy Asthma Rep       Date:  2013-06       Impact factor: 4.806

3.  Intraorbital injection of Rituximab in idiopathic orbital inflammatory syndrome: case reports.

Authors:  Gustavo Savino; Remo Battendieri; Andrea Siniscalco; Erika Mandarà; Antonino Mulè; Gianluigi Petrone; Salvatore Traina; Monica Riso
Journal:  Rheumatol Int       Date:  2014-05-31       Impact factor: 2.631

Review 4.  Molecular diagnosis: Implications for ophthalmology.

Authors:  James T Rosenbaum; Cailin H Sibley; Dongseok Choi; Christina A Harrington; Stephen R Planck
Journal:  Prog Retin Eye Res       Date:  2015-12-01       Impact factor: 21.198

5.  IgG4-associated orbital and ocular inflammation.

Authors:  Cecilia S Lee; George J Harocopos; Courtney L Kraus; Aaron Y Lee; Gregory P Van Stavern; Steven M Couch; P Kumar Rao
Journal:  J Ophthalmic Inflamm Infect       Date:  2015-05-29

6.  IgG4 immunostaining and its implications in orbital inflammatory disease.

Authors:  Amanda J Wong; Stephen R Planck; Dongseok Choi; Christina A Harrington; Megan L Troxell; Donald C Houghton; Patrick Stauffer; David J Wilson; Hans E Grossniklaus; Roger A Dailey; John D Ng; Eric A Steele; Gerald J Harris; Craig Czyz; Jill A Foster; Valerie A White; Peter J Dolman; Michael Kazim; Payal J Patel; Deepak P Edward; Hind al Katan; Hailah al Hussain; Dinesh Selva; R Patrick Yeatts; Bobby S Korn; Don O Kikkawa; James T Rosenbaum
Journal:  PLoS One       Date:  2014-10-10       Impact factor: 3.240

7.  Orbital Pseudotumor: Uncommon Initial Presentation of IgG4-Related Disease.

Authors:  Teresa Carbone; Ricardo Azêdo Montes; Beatriz Andrade; Pedro Lanzieri; Luis Mocarzel
Journal:  Case Rep Rheumatol       Date:  2015-03-09

Review 8.  IgG4-related disease presenting as panuveitis without scleral involvement.

Authors:  Kinda Najem; Larissa Derzko-Dzulynsky; Edward A Margolin
Journal:  J Ophthalmic Inflamm Infect       Date:  2017-02-27

9.  Successful corticosteroid-sparing effect of rituximab in the treatment of refractory idiopathic orbital inflammatory disease.

Authors:  Emily H Shao; Andreas Karydis; Maria Gemenetzi; Simon R J Taylor
Journal:  Case Rep Ophthalmol       Date:  2013-11-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.